A subcommittee of the health ministry’s Health Sciences Council approved plans Friday for what would be the world’s first clinical trial using induced pluripotent stem cells.
The health minister is expected shortly to give the final approval for the iPS cell clinical trial on eye disease patients planned by a team from the state-affiliated research institute Riken’s Center for Developmental Biology in Kobe.
The Riken project has already been approved by a screening panel under the subcommittee, as well as by the ethics board of the research institute.
Friday’s meeting of the subcommittee was open to the public. It was the first open screening session for the clinical research application.
Read the rest of the story: Japan health ministry subpanel OKs iPS cell clinical trial.